VANGUARD GROUP INC 13D and 13G filings for Akebia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 4:58 pm Sale | 2023-12-29 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 7,607,472 4.040% | -3,631,398 (-32.31%) | Filing |
| 2023-02-09 10:54 am Sale | 2022-12-30 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 11,238,870 6.110% | -7,120,550 (-38.78%) | Filing |
| 2022-06-09 2:15 pm Purchase | 2022-05-31 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 18,359,420 10.000% | 5,123,751 (+38.71%) | Filing |
| 2022-02-09 3:16 pm Purchase | 2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 13,235,669 7.560% | 4,800,910 (+56.92%) | Filing |
| 2021-02-10 10:30 am Purchase | 2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA | VANGUARD GROUP INC | 8,434,759 5.840% | 8,434,759 (New Position) | Filing |